AI assistant
Repare Therapeutics Inc. — Director's Dealing 2024
Apr 2, 2024
34365_dirs_2024-04-01_5f63f609-d560-43de-9109-e4b4dac2806b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Repare Therapeutics Inc. (RPTX)
CIK: 0001808158
Period of Report: 2024-03-28
Reporting Person: Segal Lloyd Mitchell (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-28 | Common Shares | S | 2650 | $4.62 | Disposed | 110049 | Indirect |
| 2024-04-01 | Common Shares | S | 2491 | $4.63 | Disposed | 107558 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Shares | 102678 | Direct |
Footnotes
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.47 to $4.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4).
F3: The change in the total shares prior to the transactions reported herein reflects a change in form of ownership from direct to indirect, which was exempt from reporting pursuant to Rule 16a-13.
F4: These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.58 to $4.65 inclusive.
F6: Includes 1,217 shares, 967 shares and 2,000 shares acquired on February 15, 2023, August 15, 2023 and February 15, 2024, respectively, under the Issuer's employee stock purchase plan.